Stem cell biotech Reneuron Group leaves the London Stock Exchange’s AIM: The company plans to stop trading on the exchange amid financial struggles, as it continues to look for investors. Reneuron first announced its challenges in February, when it said that it couldn’t find a revenue-generating partnership or funding, and requested the company to be suspended on AIM.
Jacobio Pharma grants China rights for two inhibitors to Shanghai Allist Pharmaceuticals for $28 million: The deal includes KRAS G12C inhibitor glecirasib and SHP2 inhibitor JAB-3312 in exchange for an upfront payment of $21 million (RMB 150 million) and around $7 million (RMB 50 million) of compensation for R&D costs and other payments. There are potential milestone payments of up to $98.7 million (RMB 700 million). Glecirasib was already granted priority review in May in China for patients with second-line non-small cell lung cancer with a KRAS G12C mutation.